Eli Lilly on Wednesday hit back at claims in last week's British Medical Journal that confidential company documents showed new evidence of behavioural disturbances caused by Prozac, its best-selling anti-depressant.

The US drugs company said it had reviewed the documents, which the BMJ received from an anonymous source, and found that they "reveal no new clinical or scientific information".